How to Buy Sab Biotherapeutics Stock
Sab Biotherapeutics Inc
SAB Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies.
Sab Biotherapeutics stock last closed at $3.47, down 7.22% from the previous day, and has increased 104.12% in one year. It has overperformed other stocks in the Biotechnology industry by 1.16 percentage points. Sab Biotherapeutics stock is currently +118.24% from its 52-week low of $1.59, and -47.42% from its 52-week high of $6.60.
At the moment, there are 50.95M SABS shares outstanding. The market value of SABS is $176.80M. In the past 24 hours, 626,000 SABS shares were traded.
How to Buy Sab Biotherapeutics Stock
Wondering how to invest in Sab Biotherapeutics stock? Here's how.
- Decide where to buy Sab Biotherapeutics stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you figure out where to buy Sab Biotherapeutics stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Fund your brokerage account: Select your payment method and add your information.
- Research Sab Biotherapeutics stock: The Sab Biotherapeutics ticker symbol is SABS. Is Sab Biotherapeutics stock a good investment? Should you buy shares of SABS? How do SABS's underlying business fundamentals look? Do top analysts think Sab Biotherapeutics is a good buy? Why has SABS's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if SABS is a good stock to buy).
- Make your SABS purchase: Decide if you will purchase SABS shares at the current market price or use a limit order to purchase SABS stock at a specific price.
- Get updates on your SABS investment: Create a watchlist to watch your new investment in Sab Biotherapeutics shares.
Step 1: Decide where to buy Sab Biotherapeutics stock
You need an online brokerage account to access the NASDAQ market and buy SABS shares.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best online stock brokerage. Here's why:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Tech to Healthcare, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've selected your brokerage, the next step is to fill out some personal details so you can invest in SABS today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to create a new trading account.
- Send your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you've filled out your info on one of the best stock market apps, you can securely and quickly fund your account:
Check out the video below if you need help depositing money into your investment account.
Step 4: Research Sab Biotherapeutics stock
Once you have identified the best place to buy Sab Biotherapeutics stock, it's crucial to research their stock before you buy, so you actually understand the risk and upside.
Sab Biotherapeutics Metrics
SABS Overview
WallStreetZen was built to help part-time investors perform more accurate fundamental analysis.
You can see all of the due diligence checks on SABS's stock page.
Is SABS stock properly valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge SABS's fair value.
Using relative valuations measures:
- SABS may be undervalued based on its P/E ratio of 15.77x, relative to Biotechnology industry P/E ratio of 29.06x
- SABS may be undervalued based on its P/B ratio of 1.17x, relative to Biotechnology industry P/B ratio of 4.89x
You can access more valuation research on SABS's stock here.
A quick look at SABS Financials
Pros:
- SABS has $96.59M in cash and short term investments. This is enough to cover its annual cash burn of $45.71M.
- SABS has a low debt to equity ratio of 0.14.
- SABS has cash burn of 45707767. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the SABS balance sheet.
- There are more short-term assets than short-term liabilities on the SABS balance sheet.
- Total SABS debt is lower than 5 years ago, relative to shareholder equity.
Is SABS stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 4 Wall Street analysts who research SABS, the consensus analyst rating on Sab Biotherapeutics is a Strong Buy
It's important to keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
You can dig deeper into what analysts are forecasting on the Sab Biotherapeutics stock forecast page.
SABS Momentum
Is SABS Making Money?
Last year, SABS earnings were $13.27M. In the past five year, SABS's earnings have grown by -51.14% per year. This was slower than the Biotechnology industry average of 20.73%.
Last year, SABS revenue was $0.00. During the last 5 year, SABS's revenue has grown by -100% per year. This was slower than the Biotechnology industry average of 26.82%.
Dig into SABS's earnings and revenue performance here.
Who is buying/selling SABS?
Over the last 12 months, executives and large shareholders at SABS have bought more shares than they have sold.
Andrew Moin, Director of SABS, was the latest SABS insider to buy. They bought $3,045,000.00 worth of SABS stock on Sep 29, 2025.
Dig into more about who owns SABS shares here.
Can I rely on SABS as an income stream?
No, Sab Biotherapeutics doesn't provide an income stream by paying out dividends.
What others are saying about SABS
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Make your SABS purchase
You have two primary options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually fine for most investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a specific price, use a limit order.
Hit the Open Trade button and eToro will place your order.
If you need additional assistance buying stocks on eToro, watch the how to video below:
Step 6: Get updates on your SABS investment
Now that you own some SABS shares, you'll want to keep up with your new stock purchase.
Make a watchlist to get alerted to the latest events about your SABS stock.
SABS Feed
How to Buy Stock in Sab Biotherapeutics
To reiterate, here are the 6 steps to buy stock in Sab Biotherapeutics:
- Decide where to buy Sab Biotherapeutics stock
- Create a brokerage account
- Fund your brokerage account
- Research Sab Biotherapeutics stock
- Make your SABS purchase
- Get updates on your SABS investment
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to watch your new investment in Sab Biotherapeutics, add SABS to your watchlist by clicking the button below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.